慢性阻塞性肺炎患者使用β2肾上腺素受体激动剂联合抗胆碱药物治疗的临床效果  

Clinical Effect of β2-Adrenoceptor Agonist Combined with Anticholinergic Drugs in Patients with Chronic Obstructive Pneumonia

作　　者：郑相如 郑晓文 倪晓龙 ZHENG Xiangru;ZHENG Xiaowen;NI Xiaolong(Department of Respiratory Medicine,Qingdao Jiaozhou Central Hospital,Qingdao,Shandong Province,266300 China;Department of Gastroenterology,Qingdao Jiaozhou Central Hospital,Qingdao,Shandong Province,266300 China;Department of Emergency Medicine,Qingdao Jiaozhou Central Hospital,Qingdao,Shandong Province,266300 China)

机构地区：[1]青岛市胶州中心医院呼吸内科,山东青岛266300 [2]青岛市胶州中心医院消化内科,山东青岛266300 [3]青岛市胶州中心医院急诊内科,山东青岛266300

出　　处：《系统医学》2022年第14期88-90,119,共4页Systems Medicine

摘　　要：目的 探究慢性阻塞性肺炎患者使用β_(2)肾上腺素受体激动剂联合抗胆碱药物治疗的临床效果。方法选择2020年9月—2021年9月青岛市胶州中心医院收治的慢性阻塞性肺炎患者80例,依据不同方式分为观察组(β_(2)肾上腺素受体激动剂联合抗胆碱药物治疗的方式)及对照组(单用β_(2)肾上腺素受体激动剂),各40例。对比患者的临床疗效、肺功能指标、不良反应、血气分析指标等情况。结果 与对照组的各项呼吸功能指标水平相比,观察组a/APO、pH、PaO_(2)较高,OI、PaCO_(2)较低,差异有统计学意义(P<0.05);与对照组的治疗总有效率70.00%比较,观察组95.00%明显更高,差异有统计学意义(P<0.05);与对照组不良反应发生率20.00%比较,观察组小便潴留、口干、心跳加速等发生率2.50%显著较低,差异有统计学意义(χ^(2)=7.929,P<0.05);与对照组的FEV1/FVC、FEV1%pred肺功能指标相比,观察组均明显更高,差异有统计学意义(P<0.05)。结论针对慢性阻塞性肺炎患者,通过采用β_(2)肾上腺素受体激动剂联合抗胆碱药物治疗的方式,能够改善患者的肺功能指标,提升疾病疗效,明显改善疾病预后,降低不良反应发生率,改善血气分析指标,适合应用于临床推广。Objective To investigate the clinical effect of β_(2)adrenergic receptor agonist combined with anticholinergic drugs in patients with chronic obstructive pneumonia.Methods A total of 80 patients with chronic obstructive pneumonia who were treated in Qingdao Jiaozhou Central Hospital from September 2020 to September 2021 were selected and divided into observation group(treatment with β_(2)adrenergic receptor agonist combined with anticholinergic drugs) and control group(single β_(2)adrenergic receptor agonists) according to different methods,40 cases in each group.The clinical efficacy,pulmonary function indicators,adverse reactions,and blood gas analysis indicators of the patients were compared.Results Compared with the respiratory function index levels of the control group,the a/APO,pH and PaO_(2)of the observation group were higher,the OI and PaCO_(2)were lower,and the difference was statistically significant(P<0.05).Compared with the total effective rate 70.00% the control group,the total effective rate of the observation group(95.00%) was significantly higher,and the difference was statistically significant(P<0.05).Compared with 20.00% of adverse reactions in the control group,the incidence of urinary retention,dry mouth and rapid heartbeat 2.50% in the observation group was significantly lower,and the difference was statistically significant(χ^(2)=7.929,P<0.05).Compared with the FEV1/FVC and FEV1%pred pulmonary function indexes of the control group,the observation group was significantly higher,and the difference was statistically significant(P<0.05).Conclusion For patients with chronic obstructive pneumonia,the combination of β_(2)adrenergic receptor agonists and anticholinergic drugs can improve the pulmonary function indexes of patients and improve the curative effect of the disease,which can significantly improve disease prognosis,reduce the incidence of adverse reactions,improve blood gas analysis indicators,suitable for clinical promotion.

关 键 词：慢性阻塞性肺炎 抗胆碱药物 Β2肾上腺素受体激动剂 

分 类 号：R521[医药卫生—内科学]